Europe Patient Derived Xenografts/PDX Models Market (2025-2030)
The Europe Patient Derived Xenografts/PDX Models Market was valued at $80 Million in 2025 and projected to reach to $117.9 Million by 2030, representing a compound annual growth rate of 8.1%. Europe's PDX Models market is poised for sustained growth through 2030, driven by robust pharmaceutical R&D spending, regulatory support for innovative preclinical models, and rising demand for personalized cancer therapies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Patient Derived Xenografts/PDX Models Market Trends and Insights
- Europe has emerged as a significant hub for PDX model development, driven by robust pharmaceutical R&D infrastructure, stringent regulatory frameworks, and increasing adoption of personalized medicine approaches across the continent.
- The region's investment in oncology research and translational medicine continues to fuel demand for advanced preclinical testing platforms. In Europe, the PDX market benefits from strong collaborations between academic institutions, contract research organizations (CROs), and biopharmaceutical companies seeking to improve drug efficacy and reduce development timelines.
- The region's commitment to reducing animal testing through more predictive models aligns with regulatory pressures and ethical considerations, positioning PDX technologies as a preferred alternative.
- By 2030, Europe is anticipated to maintain steady growth momentum, supported by expanding clinical applications beyond oncology and increasing funding for precision medicine initiatives across major European markets..
Key Market Statistics
- CAGR (2025-2030) 8.1% CAGR
- Market Size, 2025 ~USD 80 Million
- Forecast, 2030 ~USD 117.9 Million
- Geography Europe
Europe Patient Derived Xenografts/PDX Models Market Overview
Market Valuation & Growth :
Europe's PDX Models market is valued at $80.0 million in 2025 and is projected to reach $117.9 million by 2030, with a CAGR of 8.1%, reflecting steady expansion in personalized medicine adoption across the region.
Leading European Markets :
Germany dominates the European PDX market with $35.2 million, followed by the UK at $31.0 million and France at $19.8 million, driven by advanced pharmaceutical R&D capabilities and regulatory excellence.
Regulatory & Infrastructure Advantages :
Europe's stringent regulatory frameworks, including EMA oversight, combined with world-class research institutions and biotech clusters, position the region as a premium hub for PDX model development and validation.
Personalized Medicine Adoption :
Increasing European healthcare investment in precision oncology and companion diagnostics is accelerating PDX model utilization for drug development, clinical trial optimization, and patient-specific treatment planning.
Europe Patient Derived Xenografts/PDX Models Market Dynamics
- The region's established biotech ecosystem and academic research institutions continue to advance PDX technology adoption, particularly in oncology drug development.
- Germany, the UK, and France lead market expansion, supported by government funding initiatives and collaborative research networks.
- Regulatory harmonization across EU member states further facilitates market penetration and cross-border partnerships in PDX services..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Europe's PDX market is valued at $80.0 million in 2025 and projected to reach $117.9 million by 2030, growing at 8.1% CAGR.
- Europe leads in PDX adoption due to strong regulatory support, ethical frameworks, and advanced pharmaceutical R&D infrastructure.
- Collaborations between European academic institutions and CROs are driving innovation and market expansion across the region.
- By 2030, Europe's PDX market will benefit from expanded applications beyond oncology and increased precision medicine funding.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Europe Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 4.7 | 5 | 5.4 | 5.8 | 6.2 | 6.6 | 7 | 7.4 | 6.5 |
| CROS & CDMOS | 3.1 | 3.3 | 3.5 | 3.8 | 4 | 4.2 | 4.5 | 4.7 | 6.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 9.9 | 10.7 | 11.6 | 12.5 | 13.5 | 14.5 | 15.5 | 16.6 | 7.5 |
| TOTAL | 17.8 | 19.1 | 20.5 | 22.1 | 23.7 | 25.3 | 27 | 28.7 | 7 |
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 21.2 | 22.9 | 24.8 | 26.8 | 28.9 | 31.1 | 33.4 | 35.8 | 7.6 |
| CROS & CDMOS | 13.9 | 14.9 | 16.1 | 17.3 | 18.6 | 19.9 | 21.3 | 22.7 | 7.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 44.5 | 48.4 | 52.9 | 57.8 | 62.8 | 68.1 | 73.7 | 79.8 | 8.6 |
| TOTAL | 79.6 | 86.2 | 93.7 | 102 | 110.3 | 119 | 128.4 | 138.3 | 8.1 |
Target Audience
- Pharmaceutical Companies : European and global pharma firms require detailed market intelligence to optimize PDX model adoption in drug development pipelines, accelerate oncology programs, and enhance clinical trial success rates.
- Contract Research Organizations (CROs) : CROs operating in Europe need comprehensive market data to expand PDX service offerings, identify growth regions, benchmark competitive positioning, and develop targeted business development strategies.
- Biotech & Academic Institutions : European research centers and biotech startups utilize market insights to secure funding, establish partnerships with pharma, commercialize PDX platforms, and position themselves as innovation leaders.
- Healthcare Investors & Venture Capital : Investment firms targeting European biotech and precision medicine sectors require market forecasts, regional growth trends, and competitive dynamics to identify high-potential PDX-related investment opportunities.
- Regulatory & Government Bodies : European health authorities and policy makers use market data to inform personalized medicine strategies, allocate R&D funding, and develop regulatory frameworks supporting PDX technology adoption.
Key Companies in the Europe Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 35.2 Million |
| UK | USD 31 Million |
| France | USD 19.8 Million |
| Italy | USD 10.1 Million |
| Spain | USD 7 Million |
| Rest Of Europe | USD 24.5 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Detailed breakdown of Europe's PDX market by country, including Germany ($35.2M), UK ($31.0M), France ($19.8M), Italy, Spain, and Rest of Europe, enabling targeted market entry strategies.
- Competitive Landscape Analysis : Comprehensive insights into European PDX service providers, academic institutions, and pharmaceutical partnerships, identifying key players and market consolidation trends specific to the region.
- Regulatory & Compliance Framework : In-depth analysis of EMA regulations, EU directives, and national guidelines governing PDX model development and use, essential for companies navigating European market entry and operations.
- Growth Drivers & Opportunities : Identification of region-specific growth catalysts including increased oncology R&D budgets, personalized medicine initiatives, and government funding programs supporting PDX technology advancement in Europe.
- Strategic Partnership Insights : Intelligence on collaboration opportunities between pharmaceutical companies, CROs, academic centers, and biotech firms across Europe, facilitating market expansion and technology transfer.
Frequently asked questions
What is the current market size of PDX models in Europe?
Europe's Patient Derived Xenografts market is valued at $80.0 million in 2025 and is expected to grow to $117.9 million by 2030.
What is the growth rate of the PDX market in Europe?
Europe's PDX market is growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2030.
Why is Europe a key market for PDX model development?
Europe benefits from robust pharmaceutical R&D infrastructure, stringent regulatory frameworks, ethical considerations around animal testing, and strong collaborations between academic institutions and CROs.
Which sectors are driving PDX adoption in Europe?
Oncology research, translational medicine, personalized medicine initiatives, and precision medicine funding are primary drivers of PDX adoption across Europe.
What applications beyond oncology are expanding in Europe's PDX market?
Europe's PDX market is expanding into additional therapeutic areas including immunology, infectious disease, and rare genetic disorders as the technology matures and funding increases.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report